Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Veronese, N.; Geriatric Unit, Department of Internal Medicine and Geriatrics, University of Palermo, Palermo, 90100, Italy
Language :
English
Title :
Highly purified chondroitin sulfate: a literature review on clinical efficacy and pharmacoeconomic aspects in osteoarthritis treatment
Neogi T (2014) The epidemioloy and impact of pain in osteoarthritis. Osteoarthr Cartil 21:1145–1153. 10.1016/j.joca.2013.03.018 DOI: 10.1016/j.joca.2013.03.018
Centers for Disease Control and Prevention. Osteoarthritis. https://www.cdc.gov/arthritis/basics/osteoarthritis.htm. Accessed 19 Mar 2020
World Health Organization (2020) Chronic rheumatic conditions. https://www.who.int/chp/topics/rheumatic/en/. Accessed 15 June 2020
Rubio-Terrés C, Grupo del estudio VECTRA (2010) An economic evaluation of chondroitin sulfate and non-steroidal anti-inflammatory drugs for the treatment of osteoarthritis. Data from the VECTRA study. Reumatol Clínica (English Ed) 6:187–195. 10.1016/s2173-5743(10)70043-5 DOI: 10.1016/s2173-5743(10)70043-5
Rabenda V, Manette C, Lemmens R et al (2006) Direct and indirect costs attributable to osteoarthritis in active subjects. J Rheumatol 33:1152–1158
Poole AR (2012) Osteoarthritis as a whole joint disease. HSS J 8:4–6. 10.1007/s11420-011-9248-6 DOI: 10.1007/s11420-011-9248-6
Kolasinski SL, Neogi T, Hochberg MC et al (2020) 2019 American College of Rheumatology/Arthritis Foundation guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Care Res 72:149–162. 10.1002/acr.24131 DOI: 10.1002/acr.24131
Fuggle NR, Cooper C, Oreffo ROC et al (2020) Alternative and complementary therapies in osteoarthritis and cartilage repair. Aging Clin Exp Res 32:547–560. 10.1007/s40520-020-01515-1 DOI: 10.1007/s40520-020-01515-1
Xia W, Cooper C, Li M et al (2019) East meets West: current practices and policies in the management of musculoskeletal aging. Aging Clin Exp Res 31:1351–1373. 10.1007/s40520-019-01282-8 DOI: 10.1007/s40520-019-01282-8
Bruyère O, Honvo G, Veronese N et al (2019) An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum 49:337–350. 10.1016/j.semarthrit.2019.04.008 DOI: 10.1016/j.semarthrit.2019.04.008
Chevalier X, Conrozier T (2017) Access to highly purified chondroitin sulfate for appropriate treatment of osteoarthritis: a review. Med Access @ Point Care 1:maapoc.0000022. 10.5301/maapoc.0000022 DOI: 10.5301/maapoc.0000022
Bruyère O, Cooper C, Pelletier JP et al (2016) A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis—from evidence-based medicine to the real-life setting. Semin Arthritis Rheum 45:S3–S11. 10.1016/j.semarthrit.2015.11.010 DOI: 10.1016/j.semarthrit.2015.11.010
Punzi L, Canesi B, Carrabba M et al (2004) Italian consensus on Eular 2003 recommendations for the treatment of knee osteoarthritis. Reumatismo 56:190–201
Hochberg MC, Zhan M, Langenberg P (2008) The rate of decline of joint space width inpatientswithosteoarthritis of the knee: a systematic review and meta-analysis of randomized placebo-controlled trials of chondroitin sulfate. Curr Med Res Opin 24:3029–3035. 10.1185/03007990802434932 DOI: 10.1185/03007990802434932
Hochberg MC (2010) Structure-modifying effects of chondroitin sulfate in knee osteoarthritis: an updated meta-analysis of randomized placebo-controlled trials of 2-year duration. Osteoarthr Cartil 18:S28–S31. 10.1016/j.joca.2010.02.016 DOI: 10.1016/j.joca.2010.02.016
Honvo G, Bruyère O, Geerinck A et al (2019) Efficacy of chondroitin sulfate in patients with knee osteoarthritis: a comprehensive meta-analysis exploring inconsistencies in randomized, placebo-controlled trials. Adv Ther. 10.1007/s12325-019-00921-w DOI: 10.1007/s12325-019-00921-w
Honvo G, Bruyère O, Reginster JY (2019) Update on the role of pharmaceutical-grade chondroitin sulfate in the symptomatic management of knee osteoarthritis. Aging Clin Exp Res 31:1163–1167. 10.1007/s40520-019-01253-z DOI: 10.1007/s40520-019-01253-z
Brandt Eriksen M, Faber Frandsen T (2018) The impact of patient, intervention, comparison, outcome (PICO) as a search strategy tool on literature search quality: a systematic review. J Med Libr Assoc 106:420–431
Conte A, De Bernardi M, Palmieri L et al (1991) Metabolic fate of exogenus chondroitin sulfate in man. Arzneinittel-forsch Drug Res 41:768–772
Conte A, Volpi N, Palmieri L et al (1995) Biochemical and pharmacokinetic aspects of oral treatment with chondroitin sulfate. Arzneinittel-forsch Drug Res 45:918–925
Volpi N (2003) Oral absorption and bioavailability of ichthyic origin chondroitin sulfate in healthy male volunteers. Osteoarthr Cartil 11:433–441. 10.1016/S1063-4584(03)00051-7 DOI: 10.1016/S1063-4584(03)00051-7
Volpi N (2002) Oral bioavailability of chondroitin sulfate (Condrosulf®) and its constituents in healthy male volunteers. Osteoarthr Cartil 10:768–777. 10.1053/joca.2002.0824 DOI: 10.1053/joca.2002.0824
Bassleer CT, Combal JPA, Bougaret S et al (1998) Effects of chondroitin sulfate and interleukin-1β on human articular chondrocytes cultivated in clusters. Osteoarthr Cartil 6:196–204. 10.1053/joca.1998.0112 DOI: 10.1053/joca.1998.0112
Ronca F, Palmieri L, Panicucci P et al (1998) Anti-inflammatory activity of chondroitin sulfate. Osteoarthr Cartil 6:14–21. 10.1016/S1063-4584(98)80006-X DOI: 10.1016/S1063-4584(98)80006-X
Cohen AD, Bonneh DY, Reuveni H et al (2005) Drug exposure and psoriasis vulgaris: case-control and case-crossover studies. Acta Derm Venereol 85:299–303. 10.1080/00015550510032823 DOI: 10.1080/00015550510032823
Jomphe C, Gabriac M, Hale TM et al (2008) Chondroitin sulfate inhibits the nuclear translocation of nuclear factor-κB in interleukin-1β-stimulated chondrocytes. Basic Clin Pharmacol Toxicol 102:59–65. 10.1111/j.1742-7843.2007.00158.x DOI: 10.1111/j.1742-7843.2007.00158.x
Reveliere D, Mentz F, Nterle-Béral H et al (1998) Protective effect of chondroitin 4&6 sulfate on apoptosis of rabbit articular chondrocytes:preliminary results. Litera Rheumatologica 24:15–20
Uebelhart D, Thonar EJ, Zhang J et al (1998) Protective effect of exogenous chondroitin 4,6-sulfate in the acute degradation of articular cartilage in the rabbit. Osteoarthr Cartil 6:6–13 DOI: 10.1016/S1063-4584(98)80005-8
Monfort J, Nacher M, Montell E et al (2005) Chondroitin sulfate and hyaluronic acid (500–730 kDa) inhibit stromelysin-1 synthesis in human osteoarthritic chondrocytes. Drugs Exp Clin Res XXXI:71–76
Monfort J, Pelletier JP, Garcia-Giralt N et al (2008) Biochemical basis of the effect of chondroitin sulphate on osteoarthritis articular tissues. Ann Rheum Dis 67:735–740 DOI: 10.1136/ard.2006.068882
Nerucci F, Fioravanti A, Cicero MR et al (2000) Effects of chondroitin sulfate and interleukin-1β on human chondrocyte cultures exposed to pressurization: a biochemical and morphological study. J Osteoarthr Res Soc Int 8:279–287. 10.1053/joca.1999.0302 DOI: 10.1053/joca.1999.0302
Du Souich P, García AG, Vergés J et al (2009) Immunomodulatory and anti-inflammatory effects of chondroitin sulphate. J Cell Mol Med 13:1451–1463. 10.1111/j.1582-4934.2009.00826.x DOI: 10.1111/j.1582-4934.2009.00826.x
Conrozier T, Vignon E (1992) Effet du sulfate de chondroitine dans le traitement de l’arthrose de la hanche. Etude en double aveugle contre placebo. Litera Rheum 14:69–75
Uebelhart D, Thonar EJ, Delmas PD et al (1998) Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthr Cartil 6:39–46 DOI: 10.1016/S1063-4584(98)80011-3
Uebelhart D, Malaise M, Marcolongo R et al (2004) Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomized, double-blind, multicenter study versus placebo. Osteoarthr Cartil 12:269–276. 10.1016/j.joca.2004.01.004 DOI: 10.1016/j.joca.2004.01.004
Michel BA, Stucki G, Frey D et al (2005) Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis Rheum 52:779–786. 10.1002/art.20867 DOI: 10.1002/art.20867
Radrigán F, Gutiérrez M, Neira Ó et al (2007) Estudio de la Eficacia del Condroitín 4 y 6 Sulfato en los Síntomas de la Artrosis de Rodilla. Reumatologia 23:33–41
Kahan A, Uebelhart D, De Vathaire F et al (2009) Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 60:524–533. 10.1002/art.24255 DOI: 10.1002/art.24255
Möller I, Pérez M, Monfort J et al (2010) Effectiveness of chondroitin sulphate in patients with concomitant knee osteoarthritis and psoriasis: a randomized, double-blind, placebo-controlled study. Osteoarthr Cartil 18:S32–S40. 10.1016/j.joca.2010.01.018 DOI: 10.1016/j.joca.2010.01.018
Wildi LM, Raynauld JP, Martel-Pelletier J et al (2011) Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI. Ann Rheum Dis 70:982–989. 10.1136/ard.2010.140848 DOI: 10.1136/ard.2010.140848
Monfort J, Escudero P, Orellana C et al (2012) Condroitin sulfate decreases chemokine levels and synovitis in knee osteoarthritis patients. Arthritis Rheum 64:1101
Reginster JY, Dudler J, Blicharski T et al (2017) Pharmaceutical-grade chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: the ChONdroitin versus CElecoxib versus Placebo Trial (CONCEPT). Ann Rheum Dis 76:1537–1543. 10.1136/annrheumdis-2016-210860 DOI: 10.1136/annrheumdis-2016-210860
Wang FC, Collignon L, Reginster JY et al (1992) Effet de la prise orale de Chondroitine sulfate dans l’arthrose d’Heberden et de Bouchard. Litera Rheumatologica 14:85–90
Verbruggen G, Goemaere S, Veys EM (1998) Chondroitin sulfate: S/DMOAD (structure/disease modifying anti-osteoarthritis drug) in the treatment of finger joint OA. Osteoarthr Cartil 6:37–38. 10.1016/S1063-4584(98)80010-1 DOI: 10.1016/S1063-4584(98)80010-1
Rovetta G, Monteforte P, Molfetta G et al (2002) Chondroitin sulfate in erosive osteoarthritis of the hands. Int J Tissue React 24:29–32
Rovetta G, Monteforte P, Molfetta G et al (2004) A two-year study of chondroitin sulfate in erosive osteoarthritis of the hands: behaviour of erosions, osteophytes, pain and hand dysfunction. Drugs Exp Clin Res 30:11–16
Gabay C, Medinger-Sadowski C, Gascon D et al (2011) Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis: a randomized, double-blind, placebo-controlled clinical trial at a single center. Arthritis Rheum 63:3383–3391. 10.1002/art.30574 DOI: 10.1002/art.30574
Morreale P, Manopulo R, Galati M et al (1996) Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. J Rheumatol 23:1385–1391
Bourgeois P, Chales G, Dehais J et al (1998) Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3 × 400 mg/day vs placebo. Osteoarthr Cartil 6:25–30 DOI: 10.1016/S1063-4584(98)80008-3
Pavelka K, Manopulo R, Bucsi L (1999) Double-blind, dose-effect study of oral chondroitin 4&6 sulfate 1200 mg, 800 mg, 200 mg and placebo in the treatment of knee osteoarthritis. Litera Rheum 24:21–30
Clegg DO, Reda JD, Harris CL et al (2006) Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 354:795–80854 DOI: 10.1056/NEJMoa052771
Zegels B, Crozes P, Uebelhart D et al (2013) Equivalence of a single dose (1200 mg) compared to a three-time a day dose (400 mg) of chondroitin 4&6 sulfate in patients with knee osteoarthritis. Results of a randomized double blind placebo controlled study. Osteoarthr Cartil 21:22–27. 10.1016/j.joca.2012.09.017 DOI: 10.1016/j.joca.2012.09.017
Pelletier JP, Raynauld JP, Beaulieu AD et al (2016) Chondroitin sulfate efficacy versus celecoxib on knee osteoarthritis structural changes using magnetic resonance imaging: a 2-year multicentre exploratory study. Arthritis Res Ther 18:1–12. 10.1186/s13075-016-1149-0 DOI: 10.1186/s13075-016-1149-0
Bruyère O, Cooper C, Al-Daghri NM et al (2018) Inappropriate claims from non-equivalent medications in osteoarthritis: a position paper endorsed by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Aging Clin Exp Res 30:111–117. 10.1007/s40520-017-0861-1 DOI: 10.1007/s40520-017-0861-1
Volpi N, Maccari F (2008) Two analytical approaches to the evaluation of chondroitin sulfate in european food supplements. Sep Sci 1:3–8
Restaino OF, Finamore R, Stellavato A et al (2019) European chondroitin sulfate and glucosamine food supplements: a systematic quality and quantity assessment compared to pharmaceuticals. Carbohydr Polym 222:114984. 10.1016/j.carbpol.2019.114984 DOI: 10.1016/j.carbpol.2019.114984
Stellavato A, Restaino OF, Vassallo V et al (2019) Comparative analyses of pharmaceuticals or food supplements containing chondroitin sulfate: are their bioactivities equivalent? Adv Ther 36:3221–3237. 10.1007/s12325-019-01064-8 DOI: 10.1007/s12325-019-01064-8
Bruyère O, Scholtissen S, Neuprez A et al (2009) Impact of chondroitin sulphate on health utility in patients with knee osteoarthritis: towards economic analysis. J Med Econ 12:356–360. 10.3111/13696990903438617 DOI: 10.3111/13696990903438617
Lagnaoui R, Baumevielle M, Bégaud B et al (2006) Less use of NSAIDs in long-term than in recent chondroitin sulphate users in osteoarthritis: a pharmacy-based observational study in France. Therapie 61:341–346. 10.2515/therapie:2006063 DOI: 10.2515/therapie:2006063
